Form 4: Q32 Bio Inc. Director Acquires Stock Options
SEC Form 4 Filing
Director Isaac Manke acquired stock options for 12,767 shares of Q32 Bio Inc. on March 25, 2024.
Summary
- Isaac Manke, a director of Q32 Bio Inc., reported a transaction on March 25, 2024.
- Manke acquired stock options for 12,767 shares of common stock at an exercise price of $16.82.
- The options vest over time, with one-third vesting on March 25, 2025, and the remainder in 24 equal monthly installments, contingent on continued service.
- Following the transaction, Manke directly owns derivative securities for 12,767 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of the stock option transaction. |
| 03/25/2025 | Date when one-third of the stock options begin to vest. |
| 03/24/2034 | Expiration date of the stock options. |
| 03/27/2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.